Lung Cancer Research Review, Issue 46

In this issue:

Pembrolizumab plus chemoradiotherapy for locally advanced NSCLC
Pembrolizumab plus docetaxel for previously treated advanced NSCLC
Neoadjuvant atezolizumab and chemotherapy for resectable NSCLC
Pembrolizumab plus etoposide and platinum for first-line SCLC
Maintenance therapy with S-1 for advanced squamous cell carcinoma
Systemic treatment of brain metastases in NSCLC
Progression risk after long-term response to PD-L1 blockade
MET alterations and resistance in ALK-positive lung cancer
Denosumab for advanced NSCLC
Aprepitant for cough suppression in advanced lung cancer

Please login below to download this issue (PDF)

Subscribe